Shares of Jagsonpal Pharmaceuticals traded lower on Tuesday, November 4, falling 2.86% to Rs 220 in morning trade, after the company reported a mixed set of Q2 FY26 numbers. The stock opened weak and moved in the range of Rs 217.01 to Rs 224.05, compared to the previous close of Rs 226.48.
For the July–September quarter, Jagsonpal Pharmaceuticals reported a 9.7% year-on-year rise in net profit to Rs 126 crore, up from Rs 115 crore in the same period last year. However, revenue showed a marginal decline of 0.3% at Rs 745 crore versus Rs 747 crore a year ago.
EBITDA dipped 1.9% year-on-year to Rs 181 crore from Rs 184 crore, while operating margin contracted slightly to 24.3% from 24.6% in the previous year, reflecting a modest pressure on profitability.
The stock’s weakness comes as quarterly revenue and operating performance moderated despite profit growth. As of 9:47 AM, Jagsonpal Pharmaceuticals had a market cap of approximately Rs 14,660 crore, with a P/E ratio of 24.47.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
